Therefore, attenuating inflammation has been proposed as an effective strategy for treating psoriasis and, accordingly, inhibitors of IL17, IL23 and TNFα such as secukinumab, ustekinumab and infliximab have been launched in clinics for psoriasis treatment 30, 31. This evidence concerns the gene IL17A and psoriasis.